In colon cancer, COUP-TFII is observed in more than 57% of tumors from colon cancer patients, and there was minimal expression in normal colonic mucosa; expression of the receptor correlated with increased rates of disease-free survival. The gene discussed is NR2F2; the disease is malignant colon neoplasm.